Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2313-2320

  Goren, Marshall P ^a   Houle, Jean Marie ^b   Bush, Dorothy A ^a   Li, Jackie T ^a   Newman, Christopher E ^c   Brade, Wolfgang P ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b LAB Pharmacol Res Intl Inc   (Canada)

^c Asia Medica   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DRUG METABOLITE; EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE; IFOSFAMIDE; MESNA;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG URINE LEVEL; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CREATININE; CROSS-OVER STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MESNA; PROTECTIVE AGENTS;

EID: 0031784171     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Brock, N., Pohl, J., Stekar, J., and Scheef, W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur. J. Cancer Clin. Oncol., 18: 1377-1387, 1982.
2. Brade, W. P., Herdrich, K., and Varini, M. Ifosfamide: pharmacology, safety and therapeutic potential. Cancer Treat. Rev., 12: 1-47, 1985.
3. Fukuoka, M., Negoro, S., Masuda, N., Furuse, K., Kawahara, M., Kodama, N., Ikegami, H., Nakamura, S., Nishio, H., and Ohnoshi, T. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J. Cancer Res. Clin. Oncol., 117: 473-478, 1991.
4. Rossi, R. Nephrotoxicity of ifosfamide: moving towards understanding the molecular mechanisms. Nephrol. Dial. Transplant., 12: 1091-1092, 1997.
5. Skinner, R., Pearson, A. D., English, M. W., Price, L., Wyllie, R. A., Coulthard, M. G., and Craft, A. W. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 348: 578-580, 1996.
6. Beyer, J., Rick, O., Weinknecht, S., Kingreen, D., Lenz, K., and Siegert, W. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant., 20: 813-819, 1997.
7. Nicolau, D. P., and Hogan, K. R. National survey of use of mesna for the prevention of cyclophosphamide-induced hemorrhagic cystitis in recipients of bone marrow transplants. Mayo Clin. Proc., 67: 611-612, 1992.
8. Sencer, S. F., Haake, R. J., and Weisdorf, D. J. Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications. Transplantation (Baltimore), 56: 875-879, 1993.
9. Habs, M. R., and Schmahl, D. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2′-dithio-bis-ethane sulfonate. Cancer (Phila.), 51: 606-609, 1983.
10. Travis, L. B., Curtis, R. E., Glimelius, B., Holowary, E. J., Van, L. F., Lynch, C. F., Hagenbeek, A., Stovall, M., Banks, P. M., and Adami, J. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl. Cancer Inst., 87: 524-530, 1995.
11. Talar-Williams, C., Hijazi, Y. M., Walther, M. M., Linehan, W. M., Hallahan, C. W., Lubensky, I., Kerr, G. S., Hoffman, G. S., Fauci, A. S., and Sneller, M. C. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med., 124: 477-484, 1996.
12. Ormstad, K., Orrenius, S., Lastbom, T., Uehara, N., Pohl, J., Stekar, J., and Brock, N. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res., 43: 333-338, 1983.
13. Cox, P. J. Cyclophosphamide cystitis: identification of acrolein as the causative agent. Biochem. Pharmacol., 28: 2045-2049, 1979.
14. Brock, N., Stekar, J., Pohl, J., Niemeyer, U., and Scheffler, G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneim-Forsch., 29: 659-661, 1979.
15. James, C. A., Mant, T. G., and Rogers, H. J. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br. J. Clin. Pharmacol., 23: 561-568, 1987.
16. Stofer-Vogel, B., Cerny, T., Borner, M., and Lauterburg, B. H. Oral bioavailability of mesna tablets. Cancer Chemother. Pharmacol., 32: 78-81, 1993.
17. Pohl, J., Brock, N., Schneider, B., and Wetzelsberger, K. Zur Pharmakokinetik von Uromitexan. Methods Find. Exp. Clin. Pharmacol., 3 (Suppl. 1): 95S-101S, 1981.
18. Burkert, H., Lücker, P. W., Wetzelsberger, N., Lauterburg, B. H., and Breuel, H. P. Bioavailability of orally administered mesna. Arzneim-Forsch., 34: 1597-1600, 1984.
19. Ikeuchi, I., and Amano, T. Simultaneous determination of 2-mercaptoethanesulfonate and its disulfide in human urine by isotachophoresis. Chem. Pharm. Bull. (Tokyo), 33: 3016-3019, 1985.
20. Jones, M. S., Murrell, R. D., and Shaw, I. C. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing. Eur. J. Cancer Clin. Oncol., 21: 553-555, 1985.
21. Roth, B., Cerny, T., Brunner, K. W., and Kupfer, A. Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration (in German). Schweiz. Med. Wochenschr., 119: 1153-1158, 1989.
22. Crawhall, J. C., and Kalant, D. Measurement of biological disulfides by postcolumn sulfitolysis following separation by HPLC. Anal. Biochem., 172: 479-483, 1988.
23. Hellriegel, E. T., Bjornsson, T. D., and Hauck, W. W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther., 60: 601-607, 1996.
24. Goren, M. P., Anthony, L. B., Hande, K. R., Johnson, D. H., Brade, W. P., Li, J. T., Bush, D. A., and Frazier, M. W. Pharmacokinetics of an IV-oral versus IV mesna administration regimen in lung cancer patients receiving ifosfamide. J. Clin. Oncol., 16: 616-621, 1998.
25. Stofer-Vogel, B., Cerny, T., Kupfer, A., Junker, E., and Lauterburg, B. H. Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br. J. Cancer. 68: 590-593, 1993.
26. Duran, M., Aarsen, G., Fokkens, R. H., Nibbering, N. M. M., Cats, B. P., de Bree, P. K., and Wadman, S. K. 2-Mercaptoethanesulfonatecysteine disulfide excretion following the administration of 2-mercaptoethanesulfonate: a pitfall in the diagnosis of sulfite oxidase deficiency. Clin. Chim. Acta, 111: 47-53, 1981.